Oppenheimer & Co’s Terns Pharmaceuticals TERN Stock Holding History

Oppenheimer & Co’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,466	Closed	-$93.6K	–	1736
2025 Q3	$93.6K	Buy	+12,466	New	+$79.6K	﹤0.01%	1614

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CLGM

Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

Oppenheimer & Co's TERN Position: Q4 2025 in Review

Oppenheimer & Co sold out of Terns Pharmaceuticals (TERN) in Q4 2025, closing a stake of 12,466 shares — an estimated $93.6K sold.

Oppenheimer & Co first reported a position in TERN in Q3 2025 and held it in 1 quarter. The position peaked at $93.6K in Q3 2025. 248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

Oppenheimer & Co reported no remaining Terns Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Oppenheimer & Co sold 12,466 Terns Pharmaceuticals shares in Q4 2025, an estimated $93.6K.
Oppenheimer & Co first reported a position in Terns Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Oppenheimer & Co's Terns Pharmaceuticals position peaked at $93.6K in Q3 2025.
248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on Oppenheimer & Co's 13F filing for Q4 2025, filed 2 Feb 2026.